121 related articles for article (PubMed ID: 37962276)
1. Assessment of Swallowing Function in Patients with Head and Neck Squamous Cell Carcinoma in High vs. Low Dose Cisplatin.
Veldman A; van Oosbree A; Braun M; Gurumoorthy A; Spanos WC; Powell S
Cancer Invest; 2023 Dec; 41(10):807-815. PubMed ID: 37962276
[TBL] [Abstract][Full Text] [Related]
2. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
[TBL] [Abstract][Full Text] [Related]
4. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
5. Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.
Guo Y; Nakashima T; Cho BC; Lim DW; Yang MH; Lou PJ; Corry J; Lin JC; Zhu GP; Kim KH; Zhang B; Li Z; Hong RL; Ng JYS; Tan EM; Liu YP; Stylianou C; Spiteri C; Porceddu S
Oral Oncol; 2024 Jan; 148():106657. PubMed ID: 38101313
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy with cisplatin given once-a-week versus every-three weekly in head and neck squamous cell carcinoma: Non-inferior, equivalent, or superior?
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Oral Oncol; 2022 Nov; 134():106130. PubMed ID: 36162191
[TBL] [Abstract][Full Text] [Related]
7. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis.
Jacinto JK; Co J; Mejia MB; Regala EE
Br J Radiol; 2017 Nov; 90(1079):20170442. PubMed ID: 29053029
[TBL] [Abstract][Full Text] [Related]
8. The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
Mackiewicz J; Rybarczyk-Kasiuchnicz A; Łasińska I; Mazur-Roszak M; Świniuch D; Michalak M; Kaźmierska J; Studniarek A; Krokowicz Ł; Bajon T
Medicine (Baltimore); 2017 Dec; 96(51):e9151. PubMed ID: 29390445
[TBL] [Abstract][Full Text] [Related]
9. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.
Lee SY; Choi YS; Song IC; Park SG; Keam B; Yang YJ; Song EK; Lee HJ; Cho SH; Shim H; Park KU; Lee KH; Jo DY; Jo IS; Yun HJ;
Medicine (Baltimore); 2018 May; 97(21):e10778. PubMed ID: 29794758
[TBL] [Abstract][Full Text] [Related]
10. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis.
Helfenstein S; Riesterer O; Meier UR; Papachristofilou A; Kasenda B; Pless M; Rothschild SI
Radiat Oncol; 2019 Feb; 14(1):32. PubMed ID: 30744643
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
12. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.
Ahn D; Lee GJ; Sohn JH; Lee JE
Cancer Med; 2020 Dec; 9(24):9256-9265. PubMed ID: 33073917
[TBL] [Abstract][Full Text] [Related]
14. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
[TBL] [Abstract][Full Text] [Related]
15. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.
Schaeffers AWMA; Devriese LA; van Gils CH; Dankbaar JW; Voortman J; de Boer JP; Slingerland M; Hendriks MP; Smid EJ; Frederix GWJ; de Bree R
PLoS One; 2023; 18(11):e0294147. PubMed ID: 38011186
[TBL] [Abstract][Full Text] [Related]
16. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
[TBL] [Abstract][Full Text] [Related]
17. Effect of definitive hypo-fractionated radiotherapy concurrent with weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck.
Abdelhafiz N; Mahmoud D; Gad M; Essa H; Morsy A
J Med Life; 2023 May; 16(5):743-750. PubMed ID: 37520484
[TBL] [Abstract][Full Text] [Related]
18. Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy.
Morse RT; Ganju RG; Neeranjun R; Gan GN; Cao Y; Neupane P; Kakarala K; Shnayder Y; Lominska CE
Chemotherapy; 2023; 68(1):35-43. PubMed ID: 35882207
[TBL] [Abstract][Full Text] [Related]
19. Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
Yokota T; Zenda S; Kodaira T; Kiyota N; Fujimoto Y; Wasano K; Takahashi R; Mizowaki T; Homma A; Sasaki K; Machida R; Sekino Y; Fukuda H; ;
BMC Cancer; 2023 Nov; 23(1):1068. PubMed ID: 37932681
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
